Mostrar el registro sencillo del ítem
dc.contributor.author
Giunta, Diego Hernan
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Karlsson, Pär
dc.contributor.author
Younus, Muhammad
dc.contributor.author
Berglind, Ina Anveden
dc.contributor.author
Kieler, Helle
dc.contributor.author
Reutfors, Johan
dc.date.available
2024-07-22T12:45:44Z
dc.date.issued
2024-01
dc.identifier.citation
Giunta, Diego Hernan; Karlsson, Pär; Younus, Muhammad; Berglind, Ina Anveden; Kieler, Helle; et al.; Validation of diagnoses of liver disorders in users of systemic azole antifungal medication in Sweden; BioMed Central; Bmc Gastroenterology; 24; 1; 1-2024; 1-8
dc.identifier.issn
1471-230X
dc.identifier.uri
http://hdl.handle.net/11336/240487
dc.description.abstract
Background Liver disorders are important adverse efects associated with antifungal drug treatment. However, the accuracy of Clinical International Classifcation of Diseases (ICD)-10 codes in identifying liver disorders for register based research is not well-established. This study aimed to determine the positive predictive value (PPV) of the ICD10 codes for identifying patients with toxic liver disease, hepatic failure, and jaundice among patients with systemic antifungal treatment. Methods Data from the Swedish Prescribed Drug Register and the National Patient Register were utilized to identify adult patients who received systemic azole antifungal drugs and had a recorded diagnosis of toxic liver disease (K71.0, K71.1, K71.2, K71.6, K71.8, K71.9), hepatic failure (K72.0, K72.9), or jaundice (R17) between 2005 and 2016. The medical records of all included patients were reviewed. Prespecifed criteria were used to re-evaluate and confrm each diagnosis, serving as the gold standard to calculate PPVs with 95% confdence intervals (95% CI) for each diagnostic group. Results Among the 115 included patients, 26 were diagnosed with toxic liver disease, 58 with hepatic failure, and 31 with jaundice. Toxic liver disease was confrmed in 14 out of 26 patients, yielding a PPV of 53.8% (95% CI 33.4–73.4%). Hepatic failure was confrmed in 26 out of 38 patients, resulting in a PPV of 62.1% (95% CI 48.4–74.5%). The highest PPV was found in jaundice, with 30 confrmed diagnoses out of 31, yielding a PPV of 96.8% (95% CI 83.3–99.9%). Conclusion Among patients who received azole antifungal treatment and were subsequently diagnosed with a liver disorder, the PPV for the diagnosis of jaundice was high, while the PPVs for toxic liver disease and hepatic failure were lower.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
BioMed Central
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
Validation
dc.subject
Positive predictive value
dc.subject
Drug induced liver injury
dc.subject
Acute liver injury
dc.subject
Liver disorders
dc.subject
Toxic liver disease
dc.subject
Hepatic failure
dc.subject
Jaundice
dc.subject.classification
Medicina General e Interna
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Validation of diagnoses of liver disorders in users of systemic azole antifungal medication in Sweden
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2024-07-19T11:49:52Z
dc.journal.volume
24
dc.journal.number
1
dc.journal.pagination
1-8
dc.journal.pais
Reino Unido
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Londres
dc.description.fil
Fil: Giunta, Diego Hernan. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Karlsson, Pär. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia
dc.description.fil
Fil: Younus, Muhammad. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia
dc.description.fil
Fil: Berglind, Ina Anveden. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia
dc.description.fil
Fil: Kieler, Helle. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia
dc.description.fil
Fil: Reutfors, Johan. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia
dc.journal.title
Bmc Gastroenterology
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-023-03110-w
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1186/s12876-023-03110-w
Archivos asociados